永利股份(300230.SZ):就轉讓英東模塑 已如期收到第一期31314萬元交易價款
格隆匯9月15日丨永利股份(300230.SZ)公佈,之前披露,公司擬向關聯方蘇州英東模塑有限公司(“蘇州英東”)轉讓公司所持有的青島英東模塑科技集團有限公司(“英東模塑”)100%股權以及截至2020年12月31日公司對英東模塑的應收股利,此次交易總價為6.14億元。
根據《股權轉讓協議》的約定,蘇州英東應在協議簽署後90個自然日內即2021年9月14日前支付交易標的總價款的51%,即31314萬元。近日,公司已如期收到第一期31314萬元交易價款。 後續公司將根據進展情況持續履行信息披露義務。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.